Lactulose+Rifaximin +Bromocriptine

PreclinicalSmall molecule

IInstitute of Liver and Biliary Sciences, India

Lactulose+Rifaximin +Bromocriptine is one of 5 small molecule programs targeting Parkinsonism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParkinsonismActive, not recruiting

ParkinsonismPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Parkinsonism

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

1 2

Zonegran

AAzurity Pharmaceuticals

Approved

—3

Intravenous

IIsfahan University of Medical Sciences

Phase 2

1 4

Lactulose+Rifaximin +Bromocriptine

IInstitute of Liver and Biliary Sciences, India

Preclinical

1 5

Rozerem

SSouthern California Institute for Research and Education

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinsonism1 trial

To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02265484·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lactulose+Rifaximin +Bromocriptine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactulose+Rifaximin +Bromocriptine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactulose+Rifaximin +Bromocriptine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

Lactulose+Rifaximin +Bromocriptine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parkinsonism1 trial

References

Drug Info

Quick Facts

Related News